The InterMune Inc (NASDAQ:ITMN) on Mar. 13 announced that it has agreed to sell 7,500,000 shares of its common stock at a price to the public of $32.75 per share in an underwritten public offering. InterMune estimates net proceeds from the offering to be approximately $233.0 million, after deducting underwriting discounts and estimated offering expenses. InterMune intends to use the net proceeds from the offering to fund the commercialization activities in anticipation of the potential commercial launch of Esbriet in the United States and ongoing commercialization in Europe, to fund research and development programs with Esbriet and other compounds intended to address idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, and for general corporate purposes. InterMune Inc (NASDAQ:ITMN) shares after opening at $37.26 moved to $38.29 on last trade day and at the end of the day closed at $34.60. Company price to sales ratio in past twelve months was calculated as 42.08 and price to cash ratio as 7.64. InterMune Inc (NASDAQ:ITMN) showed a positive weekly performance of 7.82%.
The story begins with Aastrom Biosciences Inc (NASDAQ:ASTM) having gained significantly in the previous session, just as it has become normal of it in recent times. Shares rose 25.19 percent to $4.97. Although the current market price of the stock is still a far cry from its one-year high of $24.40, it is encouraging to note that a lot of positive things have been happening around the stock and it could just be a matter of time before a complete turnaround is achieved. But talk is cheap, so they say, that is why apart from the rhetoric, it is important to plunge into the facts and figures to reveal Aastrom for what it is currently and what it is shaping up to be in the future. Aastrom Biosciences Inc (NASDAQ:ASTM) shares advanced 30.58% in last trading session and ended the day on $6.49. ASTM return on equity ratio is recorded as 87.90% and its return on assets is -288.30%. Aastrom Biosciences Inc (NASDAQ:ASTM) yearly performance is -71.78%.
The most recent short interest data has been released by the NASDAQ for the 02/14/2014 settlement date, which shows a 372,586 share increase in total short interest for Enzon Pharmaceuticals Inc (ENZN), to 1,161,223, an increase of 47.24% since 01/31/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the “days to cover” metric because it considers both the total shares short and the average daily volume of shares traded. Enzon Pharmaceuticals Inc (NASDAQ:ENZN) shares moved up 16.67% in last trading session and was closed at $1.26, while trading in range of $1.08-$1.29. Enzon Pharmaceuticals Inc (NASDAQ:ENZN) year to date performance is 8.62%.
Genetic Technologies Limited (ADR) (NASDAQ:GENE) announced on 7Mar, 2014 the recent online publication in the journal Applied Health Economics and Health Policy of a study entitled, “Economic Evaluation of Using a Genetic Test to Direct Breast Cancer Chemoprevention in White Women With a Previous Breast Biopsy.” This study was a collaborative project between Genetic Technologies Limited and Archimedes Inc. of San Francisco, a healthcare modeling and analytics organization. The study examined the cost-effectiveness of utilizing BREVAGen to direct tamoxifen chemoprevention. Genetic Technologies Limited (ADR) (NASDAQ:GENE) weekly performance is 6.45%. On last trading day company shares ended up $1.65. Genetic Technologies Limited (ADR) (NASDAQ:GENE) distance from 50-day simple moving average is 1.94%. Analysts mean target price for the company is $2.50.